Oncology

Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery hopes from earlier clinical setbacks on radioligand therapeutic 177Lu-PSMA-617. The radioconjugated PSMA antagonist is a promising antagonist in an open-label, single-arm prostate cancer trial, however, its owner, ABX, made a deal of USD 12 million upfront. That has proven to be a remarkably good agreement. Sosei passes on buyout option after an investment of...